Trade

with

Alnylam Pharmaceuticals Inc
(NASDAQ: ALNY)
AdChoices
87.99
+1.81
+2.10%
After Hours :
88.44
+0.45
+0.51%

Open

87.96

Previous Close

86.18

Volume (Avg)

620.17k (689.62k)

Day's Range

86.19-88.39

52Wk Range

47.03-112.57

Market Cap.

6.58B

Dividend Rate ( Yield )

-

Beta

1.65

Shares Outstanding

76.35M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 47.17M

    • Net Income

    • -89.22M

    • Market Cap.

    • 6.58B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -1,008.42

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.65

    • Forward P/E

    • -39.06

    • Price/Sales

    • 166.67

    • Price/Book Value

    • 7.13

    • Price/Cash flow

    • -43.86

      • EBITDA

      • -82.71M

      • Return on Capital %

      • -47.76

      • Return on Equity %

      • -57.11

      • Return on Assets %

      • -47.76

      • Book Value/Share

      • 12.34

      • Shares Outstanding

      • 76.35M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Outperform
        • 1 Year Price Target

        • 108.00

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -2.57

        • Cashflow Estimate

        • -1.72

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -16.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -13.28

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -1,057.65

            • 39.38

            • Net Profit Margin

            • -1,008.42

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -105.80

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -101.70

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 12.38

              • 2.92

              • Quick Ratio

              • 12.18

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.10

              • 2.21

              • Book Value/Share

              • 12.34

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -16.23

                • 188.68

                • P/E Ratio 5-Year High

                • -21.20

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.11

                • 124.82

                • Price/Sales Ratio

                • 163.93

                • 8.72

                • Price/Book Value

                • 6.98

                • 7.95

                • Price/Cash Flow Ratio

                • -43.86

                • 45.45

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -57.11

                        (-44.20)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -47.76

                        (-19.70)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -57.11

                        (-44.20)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.05

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -92.94M
                      Operating Margin
                      -197.05
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -43.86
                      Ownership

                      Institutional Ownership

                      91.21%

                      Top 10 Institutions

                      61.26%

                      Mutual Fund Ownership

                      54.71%

                      Float

                      63.55%

                      5% / Insider Ownership

                      0.29%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Growth Company Fund

                      •  

                        5,148,491

                      • 1.17

                      • 6.74

                      • Vanguard Health Care Fund

                      •  

                        4,973,900

                      • 9.93

                      • 6.52

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        1,660,245

                      • 0.76

                      • 2.17

                      • Fidelity® Series Growth Company Fund

                      •  

                        1,226,826

                      • 1.17

                      • 1.61

                      • Vanguard Small Cap Index

                      •  

                        1,061,036

                      • 7.43

                      • 1.39

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,026,135

                      • 11.37

                      • 1.34

                      • iShares Nasdaq Biotechnology

                      •  

                        1,019,473

                      • 3.08

                      • 1.47

                      • T. Rowe Price Mid Cap Growth Fund

                      •  

                        1,000,000

                      • 0.00

                      • 1.31

                      • VA CollegeAmerica Small Cap World

                      •  

                        848,700

                      • 0.00

                      • 1.11

                      • Prudential Jennison Health Sciences

                      •  

                        787,111

                      • 0.00

                      • 1.03

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity Management and Research Company

                      •  

                        11,284,108

                      • +17.86%

                      • 14.78

                      • Wellington Management Company, LLP

                      •  

                        9,132,117

                      • +13.52%

                      • 11.96

                      • Vanguard Group, Inc.

                      •  

                        3,276,926

                      • +22.20%

                      • 4.29

                      • T. Rowe Price Associates, Inc.

                      •  

                        3,252,033

                      • -9.53%

                      • 4.26

                      • Franklin Advisers, Inc.

                      •  

                        2,538,728

                      • -2.32%

                      • 3.33

                      • Gilder Gagnon Howe & CO LLC

                      •  

                        1,995,870

                      • +4.19%

                      • 2.61

                      • Novartis AG

                      •  

                        1,697,691

                      • -58.09%

                      • 2.66

                      • BlackRock Fund Advisors

                      •  

                        1,597,915

                      • +4.65%

                      • 2.09

                      • Baillie Gifford & Co Limited.

                      •  

                        1,190,930

                      • +11.01%

                      • 1.56

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Mid Growth

                      Alnylam Pharmaceuticals Inc is a Delaware corporation that was formed in May 2003. The Company is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological ...morepathway within cells for selectively silencing and regulating the expression of specific genes. The Companys core product Alnylam 5x15, was launched in January 2011 and is focused on the development and commercialization of novel RNAi therapeutics as genetic medicines. Its genetic medicine programs are RNAi therapeutics directed towards genetically defined targets for the treatment of diseases with high unmet medical need. The Company is currently advancing the following core programs in clinical or pre-clinical development: patisiran (the International Nonproprietary Na...moreme for ALN-TTR02), an intravenously delivered RNAi therapeutic targeting transthyretin, or TTR, in development for the treatment of TTR-mediated amyloidosis, or ATTR, in patients with familial amyloidotic polyneuropathy, or FAP; ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting TTR in development for the treatment of ATTR in patients with TTR cardiac amyloidosis, including familial amyloidotic cardiomyopathy, or FAC, and senile systemic amyloidosis, or SSA; ALN-AT3, an RNAi therapeutic targeting antithrombin, or AT, in development for the treatment of hemophilia and rare bleeding disorders, or RBD; ALN-CC5, an RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases; ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1, or ALAS-1, in development for the treatment of hepatic porphyrias, including acute intermittent porphyria, or AIP; ALN-PCSsc, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, in development for the treatment of hypercholesterolemia; ALN-AAT, an RNAi therapeutic targeting alpha-1-antitrypsin, or AAT, in development for the treatment of AAT deficiency liver disease; ALN-TMP, an RNAi therapeutic targeting transmembrane protease, serine 6, or TMPRSS6, in development for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG, an RNAi therapeutic targeting angioprotein-like 3, or ANGPTL3, in development for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; and other yet to be disclosed programs. The Companys product platform provides a capability for an approach to identifying RNAi therapeutic product candidates through sequence selection, potency selection, stabilization by chemical modification, improvement of biodistribution and cellular uptake by various chemical conjugates and formulations. Its competitors include Novartis, Takeda, Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando, Quark, Silence Therapeutics plc, Tekmira, Sylentis and Dicerna Pharmaceuticals, Inc., Regulus, Rosetta Genomics, Santaris Pharma A/S, or Santaris, miRagen Therapeutics, Inc., Mirna Therapeutics, Inc. and Asuragen, Inc. The research, testing, manufacture and marketing of drug products and their delivery systems are extensively regulated in the United States and the rest of the world.lessless

                      Key People

                      Dr. John M. Maraganore,PhD

                      CEO/Director/Founder

                      John K. Clarke

                      Chairman of the Board/Director/Founder

                      Mr. Michael P. Mason

                      CFO/Chief Accounting Officer/Treasurer/Vice President, Divisional

                      Dr. Akshay K. Vaishnaw,M.D.,Ph.

                      Chief Medical Officer/Executive VP

                      Marsha H. Fanucci

                      Director

                      • Alnylam Pharmaceuticals Inc

                      • 300 Third Street

                      • Cambridge, MA 02142

                      • USA.Map

                      • Phone: +1 617 551-8200

                      • Fax: +1 617 551-8101

                      • alnylam.com

                      Incorporated

                      2003

                      Employees

                      165

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: